Polygenic risk scores stratify breast cancer risk among women with benign breast disease
JNCI: Journal of the National Cancer Institute · 01.03.2025 · 117 (3) · 456-464
DOI: 10.1093/jnci/djae255 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 16.10.2024. Verfasst von Mark E Sherman und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, United States. Hauptthemen laut MEDLINE: Breast Neoplasms, Breast Diseases, Multifactorial Inheritance. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ministère de l'Économie et de l'Innovation du Québec through Genome Québec, Agence Nationale de Sécurité Sanitaire, de l'Alimentation, de l'Environnement et du Travail, National Cancer Institute Intramural Research.
Abstract (Originalsprache)
Background
Most breast biopsies are diagnosed as benign breast disease, with 1.5- to 4-fold increased breast cancer risk. Apart from pathologic diagnoses of atypical hyperplasia, few factors aid in breast cancer risk assessment of these patients. We assessed whether a 313–single nucleotide variation (formerly single-nucleotide polymorphism) polygenic risk score stratifies risk of benign breast disease patients.
Methods
We pooled data from 5 Breast Cancer Association Consortium case-control studies (mean age = 59.9 years), including 6706 participants with breast cancer and 8488 participants without breast cancer. Using logistic regression, we estimated breast cancer risk associations by self-reported benign breast disease history and strata of polygenic risk score, with median polygenic risk score category among women without benign breast disease as the referent. We assessed interactions and mediation of benign breast disease and polygenic risk score with breast cancer risk.
Results
Benign breast disease history was associated with increased breast cancer risk (odds ratio [OR] = 1.48, 95% confidence interval [CI] = 1.37 to 1.60; P < .001). Polygenic risk score increased breast cancer risk, irrespective of benign breast disease history (Pinteraction = .48), with minimal evidence of mediation of either factor by the other. Women with benign breast disease and polygenic risk score in the highest tertile had more than twofold increased odds of breast cancer (OR = 2.73, 95% CI = 2.41 to 3.09), and those with benign breast disease and polygenic risk score in the lowest tertile experienced reduced breast cancer risk (OR = 0.79, 95% CI = 0.70 to 0.91) compared with the referent group. Women with benign breast disease and polygenic risk score in the highest decile had a 3.7-fold increase (95% CI = 3.00 to 4.61) compared with those with median polygenic risk score without benign breast disease.
Conclusion
Breast cancer risks are elevated among women with benign breast disease and increase progressively with polygenic risk score, suggesting that optimal combinations of these factors may improve risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL 32224, United States.
- Department of Quantitative Health Sciences, Mayo Clinic, Rocheseter, MN 55905, United States.
- Mayo Clinic Alix School of Medicine, Rochester, MN 55905, United States.
- Transdivisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, United States.
- Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
- Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27514, United States.
ORCID-Profile: Mark E Sherman, Stacey J Winham, Robert A Vierkant, Bryan M McCauley, Christopher G Scott, Mia M Gaudet, Melissa A Troester, Qin Wang, Joe Dennis, Kyriaki Michailidou, Therese Truong, Nadia Obi, Kristan J Aronson, Montserrat Garcia-Closas, Stephen Chanock, Xiaohong Yang, Nasim Mavaddat, Douglas F Easton, Celine M Vachon
Förderung
- Ministère de l'Économie et de l'Innovation du Québec through Genome Québec
- Agence Nationale de Sécurité Sanitaire, de l'Alimentation, de l'Environnement et du Travail
- National Cancer Institute Intramural Research
- Cancer Research UK
- Federal Ministry of Education and Research
- Department of Defence
- EU Horizon 2020 Research and Innovation Programme
- Ministère de l'Économie, Science et Innovation du Québec
Zitieren
APA
Sherman, M. E., Winham, S. J., Vierkant, R. A., McCauley, B. M., Scott, C. G., Schrup, S., Gaudet, M. M., Troester, M. A., Pruthi, S., Radisky, D. C., Degnim, A. C., Couch, F. J., Bolla, M. K., Wang, Q., Dennis, J., Michailidou, K., Guenel, P., Truong, T., Chang-Claude, J., …, & Vachon, C. M. (2025). Polygenic risk scores stratify breast cancer risk among women with benign breast disease. JNCI: Journal of the National Cancer Institute, 117(3), 456-464. https://doi.org/10.1093/jnci/djae255
Vancouver
Sherman ME, Winham SJ, Vierkant RA, McCauley BM, Scott CG, Schrup S, et al. Polygenic risk scores stratify breast cancer risk among women with benign breast disease. JNCI: Journal of the National Cancer Institute. 2025;117(3):456-464. doi:10.1093/jnci/djae255
BibTeX
@article{Sherman2025,
author = {Sherman, Mark E and Winham, Stacey J and Vierkant, Robert A and McCauley, Bryan M and Scott, Christopher G and Schrup, Sarah and Gaudet, Mia M and Troester, Melissa A and Pruthi, Sandhya and Radisky, Derek C and Degnim, Amy C and Couch, Fergus J and Bolla, Manjeet K and Wang, Qin and Dennis, Joe and Michailidou, Kyriaki and Guenel, Pascal and Truong, Therese and Chang-Claude, Jenny and Obi, Nadia and Aronson, Kristan J and Murphy, Rachel and Garcia-Closas, Montserrat and Chanock, Stephen and Ahearn, Thomas and Yang, Xiaohong and Dunning, Alison M and Mavaddat, Nasim and Pharoah, Paul D P and Easton, Douglas F and Vachon, Celine M},
title = {Polygenic risk scores stratify breast cancer risk among women with benign breast disease},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
volume = {117},
number = {3},
pages = {456--464},
doi = {10.1093/jnci/djae255}
}
EUVIMED